Evidence-Based Analysis of Drug Repurposing Research
We review peer-reviewed scientific literature on fenbendazole, ivermectin, BPC-157, and other compounds being studied for their therapeutic potential.
Ivermectin and Cancer: What the Science Really Says
Ivermectin is one of the most actively discussed repurposed drugs in oncology research. A 2024 systematic review analyzed dozens of studies and concluded it demonstrates multi-targeted anticancer activity.
Read full analysis
Fenbendazole and Cancer: The Science, The Protocols, and What You Need to Know
Fenbendazole has a scientifically compelling multi-mechanism profile targeting microtubules, glucose metabolism, p53, and angiogenesis. Here is everything you need to know about the protocols.
Read more
Joe Tippens Protocol: The Full Story and What It Looks Like in 2026
In 2017, Joe Tippens was told he had three months to live. Small-cell lung cancer, stage IV. His story sparked a global interest in fenbendazole as a potential anticancer agent.
Read more
Fenbendazole + Ivermectin: Why This Combination Is Getting Serious Attention
The scientific argument for combining fenbendazole and ivermectin is compelling — not because they do the same thing, but because they target cancer through entirely different mechanisms.
Read more
Fenbendazole 222mg vs 444mg: Which Dose Is Right for You?
Both 222mg and 444mg are used in protocols. Understanding the bioavailability argument and the cycling schedule helps you make the right choice.
Read more
BPC-157 Capsules vs. Injections: What's Safer — and What Actually Works
For the vast majority of people seeking to use BPC-157 for joint support, gut health, or general recovery, capsules are not just good enough — they're the biologically appropriate choice.
Read more